ZyVersa Therapeutics, Inc. - Common Stock (ZVSA)
Frequently Asked Questions About ZyVersa Therapeutics, Inc. - Common Stock (ZVSA)
Does ZyVersa have any collaborations or partnerships?
Yes, ZyVersa Therapeutics has established collaborations and partnerships with various academic institutions and biopharmaceutical companies. These partnerships are crucial for enhancing their research capabilities, gaining access to new technologies, and accelerating the development of their therapeutic candidates.
How can investors learn more about ZyVersa's financial performance?
Investors can learn more about ZyVersa Therapeutics' financial performance by reviewing the company's quarterly and annual reports, which are filed with the Securities and Exchange Commission (SEC). Additionally, ZyVersa provides updates through press releases, investor conference presentations, and its official website.
How does ZyVersa handle regulatory compliance?
ZyVersa Therapeutics is committed to maintaining high standards of regulatory compliance in its operations. The company works closely with regulatory agencies such as the FDA to ensure that its clinical trials and submissions adhere to established guidelines, and it has a dedicated regulatory affairs team to oversee this critical aspect of its business.
How does ZyVersa view patient engagement?
ZyVersa Therapeutics values patient engagement highly as it plays an essential role in their drug development process. The company actively seeks input from patients to understand their needs and experiences, fostering a patient-centered approach that ensures the therapies being developed are relevant and beneficial to those they aim to help.
Is ZyVersa Therapeutics publicly traded?
Yes, ZyVersa Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'ZVSA'. Being a publicly traded company allows ZyVersa to access capital markets to fund its research and development efforts while providing transparency to its investors.
What are the key products or candidates in development by ZyVersa?
ZyVersa Therapeutics has several product candidates in various stages of development, including its lead development candidate, IZC-101. IZC-101 is being investigated for its potential to treat patients with liver diseases, particularly through its unique mechanism of action aimed at reducing liver inflammation and fibrosis.
What differentiates ZyVersa from other biotechnology companies?
ZyVersa sets itself apart from other biotechnology companies by focusing on unique mechanisms of action in its drug candidates, which aim to address the underlying causes of diseases rather than merely alleviating symptoms. Additionally, the company's commitment to developing treatments for underserved patient populations enhances its differentiation in the competitive biopharmaceutical landscape.
What does ZyVersa Therapeutics, Inc. do?
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with liver diseases, inflammatory disorders, and other related conditions. The company's key programs involve the exploration of proprietary drug candidates aimed at addressing unmet medical needs, specifically in areas where current treatment options are limited.
What is the long-term vision for ZyVersa Therapeutics?
The long-term vision for ZyVersa Therapeutics is to become a leader in developing innovative treatments that improve the lives of patients with liver diseases and related conditions. By advancing its pipeline of therapeutics, the company aims to expand its market presence and contribute significantly to the field of biopharmaceuticals.
What is the mission of ZyVersa Therapeutics, Inc.?
The mission of ZyVersa Therapeutics, Inc. is to innovate and advance medical treatments that significantly improve the health outcomes of patients suffering from serious diseases, including liver diseases and inflammatory conditions. The company strives to address critical healthcare challenges by bringing transformative therapies to the market.
What is the significance of the ticker symbol 'ZVSA'?
The ticker symbol 'ZVSA' represents ZyVersa Therapeutics, Inc. on the Nasdaq stock exchange. It serves as a unique identifier for the company's shares, allowing investors and market participants to easily track its performance and trading activity in the stock market.
What is ZyVersa's approach to drug development?
ZyVersa's approach to drug development involves a rigorous scientific methodology that begins with identifying critical biological pathways involved in disease processes. The company employs advanced preclinical models and clinical trial designs to optimize the chances of success for its drug candidates, focusing on safety, efficacy, and patient outcomes.
What stages of clinical development is ZyVersa currently in?
ZyVersa is currently in the clinical development stage for its lead product candidate, which involves conducting Phase 1 and Phase 2 trials. These trials are designed to evaluate the safety and efficacy of their treatments, with the goal of advancing towards larger Phase 3 trials once sufficient data is obtained.
What therapeutic areas is ZyVersa focusing on?
ZyVersa is focusing primarily on therapeutic areas related to liver diseases, such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), along with inflammatory disorders. These areas are critical due to the increasing prevalence of these conditions and the significant unmet medical needs associated with them.
What types of investors typically invest in ZyVersa?
Investors in ZyVersa Therapeutics typically include institutional investors, venture capital firms focused on biopharmaceuticals, and individual retail investors looking for opportunities in the biotech sector. Due to the high-risk, high-reward nature of biotechnology investments, the company's investor base may vary from speculative investors to those with strong convictions in biotech innovation.
When was ZyVersa Therapeutics founded?
ZyVersa Therapeutics was founded in 2018. Since its inception, the company has focused on developing innovative therapies aimed at treating serious medical conditions, with a particular emphasis on liver diseases and inflammatory disorders.
Where is ZyVersa Therapeutics, Inc. headquartered?
ZyVersa Therapeutics, Inc. is headquartered in Fort Lauderdale, Florida. This location allows the company to be in proximity to key research and clinical institutions, fostering collaboration and innovation within the biopharmaceutical industry.
Who are the key executives at ZyVersa Therapeutics?
ZyVersa Therapeutics is led by a team of experienced executives and scientists with extensive backgrounds in the pharmaceutical industry. Key executives include the CEO, who has a proven track record in drug development and commercialization, and other leaders who bring expertise in clinical research, regulatory affairs, and business development.
Who are the target patients for ZyVersa's therapies?
ZyVersa's therapies target patients suffering from liver diseases such as Non-Alcoholic Steatohepatitis (NASH), as well as other inflammatory disorders. The focus is primarily on individuals who currently have limited options for effective treatment, providing potential for improved long-term health outcomes.
What is the current price of ZyVersa Therapeutics, Inc. - Common Stock?
The current price of ZyVersa Therapeutics, Inc. - Common Stock is 0.5873
When was ZyVersa Therapeutics, Inc. - Common Stock last traded?
The last trade of ZyVersa Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025